Corxel plans a SPAC merger to fund phase 3 of its oral GLP-1 pill CX11
The deal with Amanat Acquisition brings about $300 million in PIPE money. CX11 posted up to 11.5% weight loss at 36 weeks in phase 2.
Recap by typeshit. Full story at Fierce Biotech.